The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
Welcome to the calm before the Covid-19 storm.